Cenix BioScience and Schering AG Sign Research Agreements to Advance Several Disease Programs

02-Mar-2005

Revolutionize your production: real-time Raman analysis for maximum efficiency

Efficient inline analysis for liquids and solids

User-friendly software for effortless Design of Experiments (DoE)

Cenix BioScience GmbH and Schering AG announced that they have signed research service agreements to accelerate the latter¹s target discovery and validation efforts in several human disease programs.

Both projects, which started in the last quarter of 2004, focus on the cell-based validation by Cenix of collections of candidate genes previously identified by Schering AG as possible therapeutic drug targets. Cenix is applying its industry-leading expertise in combining high throughput (HT) RNAi with high content (HC) phenotype analyses in mammalian cells to deliver an efficient, detailed characterization of target-specific loss-of-function phenotypes. These data, along with associated insights into the functions of these targets, will provide Schering AG with the solid, patho-physiologically relevant criteria needed to prioritize targets for advancement in their drug development programs.

Cenix will apply streamlined HT validation of RNAi reagents and proprietary HT-RNAi assays including functional readouts based on rich, multi-parameter analyses. The project, which will make use of several human and mouse cell lines, will advance research programs at Schering AG. No financial terms were disclosed.

https://www.bionity.com/en/news/43869/cenix-bioscience-and-schering-ag-sign-research-agreements-to-advance-several-disease-programs.html